The relationship between metabolic dysfunction-associated fatty liver disease and low muscle mass in an asymptomatic Korean population

被引:18
|
作者
Seo, Ji Yeon [1 ]
Cho, Eun Ju [2 ]
Kim, Min Joo [3 ]
Kwak, Min-Sun [1 ]
Yang, Jong In [1 ]
Chung, Su Jin [1 ]
Yim, Jeong Yoon [1 ]
Yoon, Ji Won [3 ]
Chung, Goh Eun [1 ]
机构
[1] Seoul Natl Univ Hosp, Internal Med & Healthcare Res Inst, Dept Gastroenterol & Hepatol, Healthcare Syst Gangnam Ctr, Seoul, South Korea
[2] Seoul Natl Univ Hosp, Internal Med & Liver Res Inst, Dept Gastroenterol & Hepatol, Seoul, South Korea
[3] Seoul Natl Univ Hosp, Internal Med & Healthcare Res Inst, Dept Endocrinol, Healthcare Syst Gangnam Ctr, Seoul, South Korea
关键词
fibrosis; hepatic steatosis; low muscle mass; metabolic dysfunction; CONTROLLED ATTENUATION PARAMETER; INSULIN-RESISTANCE; HEPATIC STEATOSIS; SARCOPENIA; FIBROSIS; OBESITY;
D O I
10.1002/jcsm.13099
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Background Metabolic (dysfunction)-associated fatty liver disease (MAFLD) emphasizes the metabolic dysfunction in nonalcoholic fatty liver disease (NAFLD). Although the relationship between low muscle mass and NAFLD has been suggested, the effect of MAFLD on low muscle mass is yet to be investigated. In this study, we examined the relationship between MAFLD and low muscle mass in an asymptomatic Korean population. Methods Examinees who underwent FibroScan (R) and bioelectrical impedance analyses on the same day during the period of June 2017 to December 2019 were included. Hepatic steatosis was diagnosed using controlled attenuation parameter (CAP) with two cut-off values of 248 and 294 dB/m. Low muscle mass was defined based on appendicular skeletal muscle mass/body weight (wt) or body mass index (BMI) ratios of two standard deviations below the sex-specific mean for healthy young adults. Subjects were divided into four subgroups: diabetic MAFLD (presence of diabetes mellitus [DM]), metabolic dysfunction (MD) MAFLD (=2 metabolic abnormalities without DM), overweight MAFLD (overweight/obese without DM and <2 metabolic abnormalities) and no MAFLD. Results Among all of the 6414 subjects (mean 53.9 years of age; 85.4% male), the prevalence of MAFLD was 49.9% and 22.7% for CAP cut-off values of 248 and 294 dB/m, respectively. In the multivariate analysis, MAFLD was associated with an increased risk of both low muscle mass_wt (odds ratio [OR] 1.80, 95% confidence interval [CI] 1.38-2.35, P < 0.001) and low muscle mass_BMI (OR 1.31, 95% CI 1.01-1.70, P = 0.042). The risk of low muscle mass_wt and low muscle mass_BMI increased the most in the diabetic MAFLD subgroup compared with the no-MAFLD group (OR 2.11, 95% CI 1.51-2.96, P < 0.001 and OR 1.51, 95% CI 1.08-2.13, P = 0.017). There was an increased risk of low muscle mass_wt in the MD MAFLD subgroup (OR 1.73, 95% CI 1.31-2.28, P < 0.001). Comparable results were observed when the CAP cut-off value of 294 dB/m was applied. Conclusions The presence of MAFLD is significantly associated with increased risk of low muscle mass with varying risks according to the MAFLD subgroups. Clinicians should be aware of the differentiated risk of low muscle mass across the subgroups of MAFLD.
引用
收藏
页码:2953 / 2960
页数:8
相关论文
共 50 条
  • [41] Fasting intact insulin by mass spectrometry is associated with metabolic dysfunction-associated steatotic liver disease in youth
    Huneault, Helaina E.
    Lo, Jaclyn S.
    Bai, Shasha
    He, Zhulin
    Mcphaul, Michael J.
    Bril, Fernando
    Vos, Miriam B.
    Cree, Melanie G.
    HEPATOLOGY COMMUNICATIONS, 2024, 8 (12)
  • [42] Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States
    Kim, Donghee
    Konyn, Peter
    Sandhu, Keeryth K.
    Dennis, Brittany B.
    Cheung, Amanda C.
    Ahmed, Aijaz
    JOURNAL OF HEPATOLOGY, 2021, 75 (06) : 1284 - 1291
  • [43] Metabolic dysfunction-associated fatty liver disease and chronic hepatitis B
    Huang, Shang -Chin
    Kao, Jia-Horng
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2022, 121 (11) : 2148 - 2151
  • [44] Metabolic dysfunction-associated fatty liver disease in people living with HIV
    Michel, Maurice
    Labenz, Christian
    Armandi, Angelo
    Kaps, Leonard
    Kremer, Wolfgang Maximilian
    Galle, Peter R.
    Grimm, Daniel
    Sprinzl, Martin
    Schattenberg, Joern M.
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [45] The relationship between sarcopenia and metabolic dysfunction-associated fatty liver disease among the young and middle-aged populations
    Feng, Ziyan
    Zhao, Fanrong
    Wang, Ziyao
    Tang, Xinyi
    Xie, Yan
    Qiu, Li
    BMC GASTROENTEROLOGY, 2024, 24 (01)
  • [46] The relationship between sarcopenia and metabolic dysfunction-associated fatty liver disease among the young and middle-aged populations
    Ziyan Feng
    Fanrong Zhao
    Ziyao Wang
    Xinyi Tang
    Yan Xie
    Li Qiu
    BMC Gastroenterology, 24
  • [47] The Role of Antioxidants in the Treatment of Metabolic Dysfunction-Associated Fatty Liver Disease: A Systematic Review
    Mohammadian, Kiana
    Fakhar, Fatemeh
    Keramat, Shayan
    Stanek, Agata
    ANTIOXIDANTS, 2024, 13 (07)
  • [48] Assessment of mitochondrial function in metabolic dysfunction-associated fatty liver disease using obese mouse models
    Zhao, Qiong-Ya
    Ge, Ling-Hong
    Zhang, Kun
    Chen, Hai-Feng
    Zhan, Xin-Xin
    Yang, Yue
    Dang, Qing-Lin
    Zheng, Yi
    Zhou, Huai-Bin
    Lyu, Jian-Xin
    Fang, He-Zhi
    ZOOLOGICAL RESEARCH, 2020, 41 (05) : 539 - 551
  • [49] Diverse Functions of Macrophages in Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease: Bridging Inflammation and Metabolism
    Jang, Jun Hee
    Sung, Jin Hyun
    Huh, Jin Young
    IMMUNE NETWORK, 2025, 25 (01)
  • [50] Risk stratification using sarcopenia status among subjects with metabolic dysfunction-associated fatty liver disease
    Chun, Ho Soo
    Kim, Mi Na
    Lee, Jae Seung
    Lee, Hye Won
    Kim, Beom Kyung
    Park, Jun Yong
    Kim, Do Young
    Ahn, Sang Hoon
    Kim, Seung Up
    JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2021, 12 (05) : 1168 - 1178